<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072085</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000335441</org_study_id>
    <secondary_id>NCI-03-C-0299</secondary_id>
    <secondary_id>NCI-6210</secondary_id>
    <nct_id>NCT00072085</nct_id>
    <nct_alias>NCT00069043</nct_alias>
  </id_info>
  <brief_title>Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Immunization Of Patients With Metastatic Melanoma Using A Recombinant GP100 Protein (184V) And A Class I Restricted Peptide From The GP100 Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying immunization using two different gp100&#xD;
      protein vaccines to compare how well they work in treating patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the clinical response in patients with metastatic melanoma immunized with&#xD;
           recombinant gp100 protein (184V) emulsified in Montanide ISA-51 with or without&#xD;
           gp100:209-217 (210M) peptide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the toxicity profile of these immunizations in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are assigned to 1 of 2 cohorts according to&#xD;
      HLA-A2*0201 status. Patients assigned to cohort 1 are then randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Cohort 1 (HLA-A2*0201-positive patients): Patients are randomized to 1 of 2 treatment&#xD;
           arms.&#xD;
&#xD;
             -  Arm I: Patients receive immunization comprising recombinant gp100 protein (184V)&#xD;
                emulsified in Montanide ISA-51 subcutaneously (SC) on days 1, 22, 43, and 64 (1&#xD;
                course).&#xD;
&#xD;
             -  Arm II: Patients receive immunization comprising recombinant gp100 protein (184V)&#xD;
                and gp100:209-217 (210M) peptide emulsified in Montanide ISA-51 SC on days 1, 22,&#xD;
                43, and 64 (1 course).&#xD;
&#xD;
        -  Cohort 2 (HLA-A2*0201-negative patients): Patients receive immunization as in cohort 1,&#xD;
           arm I.&#xD;
&#xD;
      In both cohorts, treatment continues in the absence of rapid disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      In both cohorts, patients are evaluated 3-4 weeks after the fourth immunization. Patients&#xD;
      achieving stable disease or a partial response receive retreatment according to their&#xD;
      assigned cohort. Patients with progressive disease who are eligible for interleukin-2 (IL-2)&#xD;
      receive retreatment according to their assigned cohort AND high-dose IL-2 IV over 15 minutes&#xD;
      3 times daily on days 2-5, 23-26, 44-47, and 65-68 (1 course). Patients receive up to 3&#xD;
      retreatment courses. Patients achieving a complete response (CR) receive 1 retreatment course&#xD;
      beyond CR. Patients with progressive disease who are ineligible for IL-2 administration are&#xD;
      removed from the study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45-75 patients (30-50 for cohort 1 [15-25 per treatment arm]&#xD;
      and 15-25 for cohort 2) will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Progressive disease during or after prior standard treatment with or without&#xD;
             interleukin-2&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count greater than 500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  ALT and AST less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic cardiac disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No known immunodeficiency disease&#xD;
&#xD;
          -  No known hypersensitivity to study agents&#xD;
&#xD;
          -  No form of primary or secondary immunodeficiency&#xD;
&#xD;
          -  No opportunistic infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior gp100 peptide vaccine&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 6 weeks since prior nitrosoureas&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior recent (within the past 3 weeks) minor surgical procedures allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy (toxicity no greater than grade 1)&#xD;
&#xD;
          -  More than 3 weeks since prior systemic anticancer therapy&#xD;
&#xD;
          -  No other concurrent systemic anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

